During the past decade, AMR Kansas City conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AMR Kansas City" #1 sponsor was "Ambrx, Inc." with 1 trials, followed by "British American Tobacco (Investments) Limited" with 1 trials sponsored, "Dragonfly Therapeutics" with 1 trials sponsored, "Emergent BioSolutions" with 1 trials sponsored and "HUYABIO International, LLC." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AMR Kansas City" #1 collaborator was "Advaccine (Suzhou) Biopharmaceuticals Co., Ltd." with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Catalyst Clinical Research, LLC" with 1 trials as a collaborator, "Celerion" with 1 trials as a collaborator and "United States Department of Defense" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "AMR Kansas City" are "Botulinum Toxin" (1 trials), "COVID-19 Disease" (1 trials), "Chikungunya Virus" (1 trials), "Coronavirus Infection" (1 trials) and "HER2 Amplified Solid Tumors" (1 trials). Many other conditions were trialed in "AMR Kansas City" in a lesser frequency.

Most popular intervention types in "AMR Kansas City" are "Drug" (8 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "ARX788" (1 trials), "Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose" (1 trials), "Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose" (1 trials) and "CELLECTRA® 2000" (1 trials). Other intervention names were less common.

The vast majority of trials in "AMR Kansas City" are 10 trials for "All" genders.

Currently, there are NaN active trials in "AMR Kansas City". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in AMR Kansas City, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in AMR Kansas City, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".